Acute Myeloid Leukemia With Plasmacytoid Differentiating Cutaneous Lesions: A Case of Double Identity or Active Transformation.
Acute myeloid leukemia (AML) with plasmacytoid dendritic cell differentiation (pDC-AML) is a newly described subtype of leukemia with features resembling blastic plasmacytoid dendritic cell neoplasm (BPDCN).
Herein, we present a case of pDC-AML in which bone marrow findings were best classified as AML, whereas cutaneous manifestations by morphology and immunophenotype were highly suggestive of a pDC neoplasm.
A high-dose cytarabine with anthracycline backbone and venetoclax was administered based on efficacy in AML and BPDCN, respectively. The patient achieved complete remission as well as resolution of FDG-avid activity by PET-CT imaging.
This report highlights that clinical correlation with immunophenotype and molecular testing is important in distinguishing these unique entities to guide appropriate diagnosis and management.
Herein, we present a case of pDC-AML in which bone marrow findings were best classified as AML, whereas cutaneous manifestations by morphology and immunophenotype were highly suggestive of a pDC neoplasm.
A high-dose cytarabine with anthracycline backbone and venetoclax was administered based on efficacy in AML and BPDCN, respectively. The patient achieved complete remission as well as resolution of FDG-avid activity by PET-CT imaging.
This report highlights that clinical correlation with immunophenotype and molecular testing is important in distinguishing these unique entities to guide appropriate diagnosis and management.
Authors
Lee Lee, Griffin Griffin, Jeyakumar Jeyakumar, Gamayo Gamayo, Rezk Rezk, Naqvi Naqvi
View on Pubmed